Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta‐analysis of randomized clinical trials

2019 ◽  
Vol 94 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Babikir Kheiri ◽  
Ahmed Abdalla ◽  
Mohammed Osman ◽  
Mahmoud Barbarawi ◽  
Yazan Zayed ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Clinical Trials ◽  
Percutaneous Coronary Intervention ◽  
Coronary Artery ◽  
Antiplatelet Therapy ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Coronary Intervention ◽  
Percutaneous Coronary ◽  
Artery Disease

scholarly journals P2Y12 blocker monotherapy after percutaneous coronary intervention

2021 ◽  
Author(s):  
F. W. A. Verheugt ◽  
P. Damman ◽  
S. A. J. Damen ◽  
J. J. Wykrzykowska ◽  
E. C. I. Woelders ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Percutaneous Coronary Intervention ◽  
Coronary Artery ◽  
Antiplatelet Therapy ◽  
Coronary Intervention ◽  
Randomised Trials ◽  
Novel Therapy ◽  
Percutaneous Coronary ◽  
Artery Disease ◽  
Meta Analyses

AbstractFor secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential. For patients undergoing a percutaneous coronary intervention (PCI) temporary dual antiplatelet platelet therapy (DAPT: aspirin combined with a P2Y12 blocker) is mandatory, but leads to more bleeding than single antiplatelet therapy with aspirin. Therefore, to reduce bleeding after a PCI the duration of DAPT is usually kept as short as clinically acceptable; thereafter aspirin monotherapy is administered. Another option to reduce bleeding is to discontinue aspirin at the time of DAPT cessation and thereafter to administer P2Y12 blocker monotherapy. To date, five randomised trials have been published comparing DAPT with P2Y12 blocker monotherapy in 32,181 stented patients. Also two meta-analyses addressing this novel therapy have been presented. P2Y12 blocker monotherapy showed a 50–60% reduction in major bleeding when compared to DAPT without a significant increase in ischaemic outcomes, including stent thrombosis. This survey reviews the findings in the current literature concerning P2Y12 blocker monotherapy after PCI.

Sign in / Sign up

Export Citation Format

Share Document